Showing 3,121 - 3,140 results of 3,304 for search '"clinical trial"', query time: 0.11s Refine Results
  1. 3121

    The analgesic effectiveness of auriculotherapy for acute postoperative pain: A systematic review and meta-analysis by Guilin Zhang, Guixing Xu, Yao Tang, Lingxue Zhang, Xi Chen, Xingyu Liang, Ling Zhao, Dehua Li

    Published 2025-03-01
    “…Methods: We searched the MEDLINE, Web of Science, Embase, Cochrane Library, CINAHL Complete, and ClinicalTrials.gov from inception to January 23, 2024 for all randomized controlled trials (RCTs) of auriculotherapy in the treatment of APP. …”
    Get full text
    Article
  2. 3122
  3. 3123

    A randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patientsResearch in context by Yuji Hiromatsu, Eri Ishikawa, Ai Kozaki, Yasuhiro Takahashi, Mika Tanabe, Ken Hayashi, Yukihiro Imagawa, Kazutoyo Kaneda, Masashi Mimura, Xiaoxian Dai, Tomoko Hayashida, Takashi Akamizu

    Published 2025-02-01
    “…This trial was registered at Japan Registry for Clinical Trials (jRCT2031210453). Findings: Fifty-four patients were randomised (teprotumumab, 27; placebo, 27) between February and November 2022. …”
    Get full text
    Article
  4. 3124

    Safety and efficacy of edoxaban monotherapy after bioabsorbable polymer everolimus-eluting stent implantation in a human-like coronary atherosclerotic porcine model by Daisuke Kitano, Suguru Migita, Yuxin Li, Yutaka Koyama, Katsunori Fukumoto, Sayaka Shimodai-Yamada, Akira Onishi, Daiichiro Fuchimoto, Shunichi Suzuki, Yoshiyuki Nakamura, Atsushi Hirayama, Hiroyuki Hao, Yasuo Okumura

    Published 2025-03-01
    “…These results provide important preclinical evidence supporting the potential of DOAC monotherapy as an antithrombotic strategy after DES implantation and warrant further investigation in clinical trials.…”
    Get full text
    Article
  5. 3125

    Psychometric properties and meaningful change thresholds for the QOL-E instrument in patients with myelodysplastic neoplasms by Esther Natalie Oliva, Shien Guo, Jennifer Lord-Bessen, Aylin Yucel, Roberto Latagliata, Massimo Breccia, Giuseppe A. Palumbo, Grazia Sanpaolo, Marta Riva, Valeria Santini, Uwe Platzbecker, Guillermo Garcia-Manero, Pierre Fenaux, Christopher G. Pelligra

    Published 2025-02-01
    “…The objective of this study was to evaluate the psychometric performance of the QOL-E in patients with LR-MDS.MethodsData from four clinical trials in MDS (MEDALIST, DARB-MDS, EQoL-MDS, and RevMDS trials) were used to assess construct validity, reliability, and responsiveness. …”
    Get full text
    Article
  6. 3126

    A multidimensional assessment of adverse events associated with paliperidone palmitate: a real-world pharmacovigilance study using the FAERS and JADER databases by Siyu Lou, Zhiwei Cui, Yingyong Ou, Junyou Chen, Linmei Zhou, Ruizhen Zhao, Chengyu Zhu, Li Wang, Zhu Wu, Fan Zou

    Published 2025-01-01
    “…Abstract Objective Paliperidone palmitate is a second-generation antipsychotic that has undergone extensive investigation in clinical trials. However, real-world studies assessing its safety in large populations are lacking. …”
    Get full text
    Article
  7. 3127

    Evaluating the feasibility, sensitivity, and specificity of next-generation molecular methods for pleural infection diagnosis by Peter T. Bell, Timothy Baird, John Goddard, Olusola S. Olagoke, Andrew Burke, Shradha Subedi, Tiana R. Davey, James Anderson, Derek S. Sarovich, Erin P. Price

    Published 2025-02-01
    “…These data will help to inform the design of larger prospective clinical trials and identify potential obstacles to be overcome before next-generation sequencing technologies can be integrated into routine clinical practice.…”
    Get full text
    Article
  8. 3128

    Safety and efficacy of filgotinib in patients with rheumatoid arthritis: final results of the DARWIN 3 long-term extension study by Arthur Kavanaugh, Paul Emery, René Westhovens, Mark C Genovese, Kevin L Winthrop, Rieke Alten, Dick de Vries, Lorenzo Dagna, Patrick Verschueren, Maria Greenwald, Regina Cseuz, Robin Besuyen, Vikas Modgill, Ly Huong Le

    Published 2025-01-01
    “…Objectives DARWIN 3 (ClinicalTrials.gov: NCT02065700) assessed the safety and efficacy of filgotinib in a long-term extension (LTE) of two phase II randomised controlled rheumatoid arthritis (RA) trials.Methods Eligible patients completing the 24-week DARWIN 1 (filgotinib plus methotrexate) and DARWIN 2 (filgotinib monotherapy) trials could enrol. …”
    Get full text
    Article
  9. 3129
  10. 3130
  11. 3131
  12. 3132

    Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma by Wei Gao, Tong Ding, Beicheng Sun, Nan Li, Fang Gao, Meng Jia, Mitchell Ho, Na Li, Luan Sun, Zhanhui Gao, Lei Ao, Sujuan Ma, Peihua Lu, Shaochang Jia

    Published 2021-04-01
    “…Therefore, sGPC3 acted as dominant negative regulators when competed with cell surface GPC3 to bind anti-GPC3 CAR-T cells, leading to an inhibitory effect on CAR-T cells in HCC.Conclusions We provide a proof-of-concept study demonstrating that GPC3 shedding might cause worse response to CAR-T cell treatment by competing with cell surface GPC3 for CAR-T cell binding, which revealed a new mechanism of tumor immune escape in HCC, providing a novel biomarker for patient enrolment in future clinical trials and/or treatments with GPC3-targeted CAR-T cells.…”
    Get full text
    Article
  13. 3133
  14. 3134
  15. 3135

    Evaluation of Biologics ACE2/Ang(1–7) Encapsulated in Plant Cells for FDA Approval: Safety and Toxicology Studies by Henry Daniell, Geetanjali Wakade, Smruti K. Nair, Rahul Singh, Steven A. Emanuel, Barry Brock, Kenneth B. Margulies

    Published 2024-12-01
    “…Vital biomarkers and organs were not adversely affected despite the 10-fold higher absorption in the tissues, demonstrating the safety for the first in-human clinical trials of ACE2/Ang(1–7). The NOAEL observed in the rats was 2.5–7.5-fold higher than that of the anticipated efficacious therapeutic dose in humans for the treatment of cardiopulmonary disorders, and it was 314-fold higher than the NOAEL for topical delivery via chewing gum. …”
    Get full text
    Article
  16. 3136

    Hard and soft tissue alterations after the application of different soft tissue grafting materials during immediate dental implant placement: a systematic review and Bayesian netwo... by Ali Azadi, Fatemeh Rezaei, Atoosa Yazdani, Kimia Hejazi, Aryousha Moallem Savasari, Reza Amid, Mahdi Kadkhodazadeh

    Published 2025-02-01
    “…in PubMed, Scopus, and ISI Web of Science, randomized controlled clinical trials (RCTs) using different soft tissue grafts were identified and analyzed using a Bayesian random-effect network meta-analysis framework. …”
    Get full text
    Article
  17. 3137
  18. 3138
  19. 3139

    Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors by Alfred Zippelius, Petra Herzig, Pratiksha Gulati, Christian Klein, Marta Trüb, Kirsten D Mertz, Robert Rosenberg, Viola Heinzelmann-Schwarz, Mark Wiese, Didier Lardinois, Pablo Umana, Marina Natoli, Klas Hatje, Fabian Junker, Zhiwen Jiang, Iakov I Davydov, Markus Germann, Daniel Marbach, Adrian Zwick, Patrick Weber, Stefan Seeber, Lothar Tietze, Laura Codarri-Deak, Henry Kao

    Published 2022-11-01
    “…Interestingly, LAG-3 protein upregulation was detected as a unique pharmacodynamic effect mediated by PD1-LAG3, but not by PD1-TIM3 or anti-PD-1.Conclusions Our in vitro system reliably assessed responses to bispecific antibodies co-targeting PD-1 together with LAG-3 or TIM-3 using patients’ tumor infiltrating immune cells and revealed transcriptional and phenotypic imprinting by bispecific antibody formats currently tested in early clinical trials.…”
    Get full text
    Article
  20. 3140

    Effectiveness–implementation hybrid-2 randomised trial of a collaborative Shared Care Model for Detecting Neurodevelopmental Impairments after Critical Illness in Young Children (D... by Paula Lister, Kristen Gibbons, Zephanie Tyack, Luregn J Schlapbach, Samudragupta Bora, Maria Isabel Castillo, James Best, Debbie Long, Helen G Liley, Belinda Dow, Kerri-Lyn Webb, Christian Stocker, Debra Thoms, Carolyn Wharton, Lori Matuschka

    Published 2022-07-01
    “…Dissemination of the outcomes of the study is expected via publication in a peer-reviewed journal, presentation at relevant conferences, and via social media, podcast presentations and open-access medical education resources.Registration details The trial was prospectively registered with the Australian New Zealand Clinical Trials Registry as ‘Pilot testing of a collaborative Shared Care Model for Detecting Neurodevelopmental Impairments after Critical Illness in Young Children’ (the DAISY Pilot Study).Trial registration number ACTRN12621000799853.…”
    Get full text
    Article